内容紹介
Summary
Somatic multiple-gene panel tests for cancer genome medicine and companion diagnostics, which diagnose or screen hereditary tumor syndromes along with selecting patients suitable for specific anticancer drugs, have been introduced to the clinical setting. Germline multi-gene panel tests also have begun to be used. In this situation, the traditional flow of the medical treatment for hereditary tumor syndromes is rapidly changing in Japan. It is anticipated that cases whose complicated germline genetic information is detected through approaches different from the traditional genetic testing flow will increase. It is necessary to develop systems that can lead to preventive intervention and treatment of cancer patients and previvors in his/her relatives through interpretation and communication of genetic information. In future medical treatment for hereditary tumor syndrome, flexible responses for various issues in a manner free from traditional are required not to be confined to the frame of conventional medical genetics.
要旨
体細胞の多遺伝子パネル検査(がんゲノム医療)やがん治療薬の適応判定とともに遺伝性腫瘍症候群を診断するあるいはスクリーニングにつながるコンパニオン診断が臨床の場に導入されている。さらに,多遺伝子パネルを用いた遺伝学的検査も普及しはじめ,わが国の従来の遺伝性腫瘍診療の流れが急速に変化している。これまでと異なる検査実施の流れの結果,複雑な生殖細胞系列の遺伝情報が検出されるケースの増加も予測され,これらを解釈し,伝達し,遺伝性腫瘍診療の目的であるがん患者やその血縁の未発症者の予防介入や治療につなげられる体制整備が必須である。これからの遺伝性腫瘍診療には,従来の遺伝医療の枠にとらわれない柔軟な対応が求められる。
目次
Somatic multiple-gene panel tests for cancer genome medicine and companion diagnostics, which diagnose or screen hereditary tumor syndromes along with selecting patients suitable for specific anticancer drugs, have been introduced to the clinical setting. Germline multi-gene panel tests also have begun to be used. In this situation, the traditional flow of the medical treatment for hereditary tumor syndromes is rapidly changing in Japan. It is anticipated that cases whose complicated germline genetic information is detected through approaches different from the traditional genetic testing flow will increase. It is necessary to develop systems that can lead to preventive intervention and treatment of cancer patients and previvors in his/her relatives through interpretation and communication of genetic information. In future medical treatment for hereditary tumor syndrome, flexible responses for various issues in a manner free from traditional are required not to be confined to the frame of conventional medical genetics.
要旨
体細胞の多遺伝子パネル検査(がんゲノム医療)やがん治療薬の適応判定とともに遺伝性腫瘍症候群を診断するあるいはスクリーニングにつながるコンパニオン診断が臨床の場に導入されている。さらに,多遺伝子パネルを用いた遺伝学的検査も普及しはじめ,わが国の従来の遺伝性腫瘍診療の流れが急速に変化している。これまでと異なる検査実施の流れの結果,複雑な生殖細胞系列の遺伝情報が検出されるケースの増加も予測され,これらを解釈し,伝達し,遺伝性腫瘍診療の目的であるがん患者やその血縁の未発症者の予防介入や治療につなげられる体制整備が必須である。これからの遺伝性腫瘍診療には,従来の遺伝医療の枠にとらわれない柔軟な対応が求められる。